臨床泌尿器科60巻12号

2006年11月発行

特集 ここが知りたい―癌薬物療法

再燃前立腺癌に対する薬物療法

著者： 三木恒治¹ 沖原宏治¹

所属機関： ¹京都府立医科大学大学院泌尿器機能再生外科学

ページ範囲：P.897 - P.904

文献概要

　一次内分泌療法後の再燃前立腺癌症例に対する治療法を大別すると，1）二次内分泌療法，2）化学療法，3）分子標的治療ならびに遺伝子治療，4）ビスフォスフォネート製剤やハーブ療法を代表とする緩和的治療が挙げられる。1）から4）の治療法をどの時点で行えばよいかの確立されたレジメンはいまだないが，わが国においては患者の年齢，QOL，再燃癌の進行度に基づき，個々の状況に応じて選択しているのが実情と考えられる。本稿では，現実的により多数の施設で実施可能な経口内服療法を念頭におき，アンドロゲン交替療法，エストラムスチンやデキサメサゾンを用いた内服療法，タキソテールなどの抗癌剤を用いた化学療法を中心に解説した。

参考文献

1）日本泌尿器科学会・日本病理学会（編）：前立腺癌取扱い規約 第3版．金原出版，東京，pp85，2001

2）European Association of Urology：Guidelines on Prostate Cancer, 2005 edition. pp91-106, 2005

3）Kelly WK and Scher HI：Prostate specific antigen decline after antiandrogen withdrawal：the flutamide withdrawal syndrome. J Urol 149：607-611, 1993

4）Nieh PT：Withdrawal phenomenon with the antiandrogen casodex. J Urol 153：1070-1072, 1995

5）Miyake H, Hara I and Eto H：Clinical outcome of maximum androgen blockade using flutamide as second-line hormonal therapy for hormone-refractory prostate cancer. BJU Int 96：791-795, 2005

6）Kojima S, Suzuki H, Akakura K, et al：Alternative antiandrogens to treat prostate cancer relapse after initial hormone therapy. J Urol 171（2 Pt 1）：679-683, 2004

7）Okihara K, Ukimura O, Kanemitsu N, et al：Clinical efficacy of alternative antiandrogen deprivation therapy in Japanese men with relapsed prostate cancer after first line hormonal therapy. Int J Urol（in press）

8）Lam JS, Leppert JT, Vemulapalli SN, et al：Secondary hormonal therapy for adcvanced prostate cancer. J Urol 175：27-34, 2006

9）Sher HI, Liebertz C, Kelly WK, et al：Bicalutamide for advanced prostate cancer：the natural versus treated history of disease. J Clin Oncol 15：2928-2938, 1997.

10）Joyce R, Fenton MA, Rode P, et al：High dose bicalutamide for androgen independent prostate cancer：effect of prior hormonal therapy. J Urol 159：149-153, 1998

11）Small EJ, Halabi S, Dawson NA, et al：Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients a phase Ⅲ trail（CALGB 9583）. J Clin Oncol 22：1025-1033, 2004

12）Kruit WH, Stoter G and Klijn JG：Effect of combination therapy with aminoglutethimide and hydrocortisone on prostate-specific antigen response in metastatic prostate cancer refractory to standard endocrine therapy. Anticancer Drugs 15：843-847, 2004

13）Nishimura K, Nonomura N, Yasunaga Y, et al：Low doses of oral dexamethasone for hormone-refractory prostate carcinoma. Cancer 89：2570-2576, 2000

14）西村和郎，高原史郎，野々村祝夫，他：再燃前立腺癌．抵抗性前立腺癌の治療法．日本臨牀60（増刊11）：266-271，2002

15）Ukimura O, Kamoi K, Hongo F, et al：Oral administration of dexamethasone in combination with UFT and cyclophosphamide for the treatment of hormone-refractory prostate cancer. J Clin Oncol 20（part 2 of 2）：165b, 2001

16）Yagoda T：Estramustine phosphate in the treatment of advanced prostate cancer. J Urol 145（Suppl）：384. abstract 686, 1991

17）Iversen P, Rasmussen F, Asmussen C, et al：Estramustine phosphate versus placebo as second line treatment after orchiectomy in patients with metastatic prostate cancer：DAPROPA study 9002. Danish Prostatic Cancer Group. J Urol 157：929-934, 1997

18）Nishimura K, Miki T, et al：Oral combination of cyclophosphamide, uracil plus tegafur and estramustine for hormone-refractory prostate cancer. Oncology 60：49-54, 2001

19）Kantoff PW, Halabi S, Conaway M, et al：Hydrocortisone with or without mitoxantrone in men with hormone refractory prostate cancer：results of the Cancer and Leukemia Group B 9182 study. J Clin Oncol 17：2506-2513, 1999

20）Tannock IF, de Wit R, Berry WR, et al：Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351：1502-1512, 2004

21）Petrylak DP, Tangen CM, Hussain MHA, et al：Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced prostate cancer. N Engl J Med 351：1513-1520, 2004

22）Kojima T, Shimazui T, Onozawa M, et al：Weekly administration of docetaxel in patients with hormone-refractory prostate cancer：a pilot study on Japanese patients. Jpn J Clin Oncol 34：137-141, 2004

23）Miyoshi Y, Uemura H, Nakamura M, et al：Treatment of androgen-independent, hormone-reforactory prostate cancer with docetaxel in Japanese patients. Int J Clin Oncol 10：182-186, 2005

24）日本泌尿器科学会（編）：前立腺癌診療ガイドライン2006年版．pp203，2006

25）Savares DM, Halabi S, Hars V, et al：PhaseⅡ study docetaxel, estramustine, and low dose hydrocortisone in men with hormone-refractory prostate cancer：a final report of CALGB 9780. Cancer and Leukemia Group B. J Clin Oncol：19：2509-2516. 2001

26）Dahut WL, Gulley JL, Arlen PM, et al：Randomized phaseⅡ trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J Clin Oncol：22：2532-2539, 2004

27）白木良一，桑原勝孝，櫻井孝彦，他：ホルモン不応性前立腺癌に対するタキサン系抗癌剤の有用性．泌尿紀要52：481-485，2005

28）小中弘之，溝上　敦，越田　潔，他：進行性前立腺癌に対するビスフォスフォネート併用療法の検討．泌外19：587-593，2006

29）Saad F, Gleason DM, Murray R, et al：A randomized placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 96：879-882, 2004

30）日本泌尿器科学会（編）：前立腺癌診療ガイドライン2006年版．pp204，2006

31）Vogelzang NJ, Nelson JB, Schulman CC, et al：meta-analysis of clinical trial of atrasentan 10mg in metastatic hormone-refractory prostate cancer. J Clin Oncol 23：393s, 2005

32）Ziada A, Bargawi A, Globe LM, et al：The use of trastuzumab in the treatment of hormone refractory prostate cancer：phaseⅡ trial. Prostate 61：332-337, 2004

33）Canil CM, Moore MJ, Winquist E, et al：Randomized phaseⅡ study of two doses of gefitinib in hormone refractory prostate cancer：a trial of the National Cancer Institute of Canada-Clinical Trials Group. J Clin Oncol 23：455-460, 2005

34）Mathew P, Thall PF, Jones D, et al：Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel：a modular phaseⅠ trial in androgen-independent prostate cancer. J Clin Oncol 22：3323-3329, 2004

35）Drake MJ, Robson W, Mehta P, et al：An open-label phaseⅡ study of low dose thalidomide in androgen-independent prostate cancer. Br J Cancer 88：822-827, 2003

36）Figg WD, Arlen P, Gullery J, et al：A randomized phaseⅡ trail of decetaxel plus thalidomide in androgen-independent prostate cancer. Semin Oncol 28：62-66, 2001

37）Papandreou CN, Daliani DD, Nix D, et al：PhaseⅠ trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol 22：2108-2121, 2004

38）上村博司，窪田吉信：アンギオテンシンⅡ受容体ブロッカーによる内分泌抵抗性前立腺癌に対する分子標的治療法の検討．泌外19：509-513，2006

39）Beer TM, Eilers KM, Garzotto M, et al：Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer. J Clin Oncol. 21：123, 2003

40）Small EJ, Schellhammer PF, Higano CS, et al：Results of a placebo-controlled phaseⅡ trail of immunotherapy with APC8015 for patients with hormone refractory prostate cancer（HRPC）. ASCO 2005, abstract 4500

41）Sowery RD, So AI and Gleave ME：Novel therapy in advanced prostate cancer. EAU-EBU UPDATE SERIES 4：161-170, 2006